Epiphany Biosciences Reports Initiation Of Phase 2 Study Of Valomaciclovir For The Treatment Of Acute Infectious Mononucleosis

Sex hormone unchangeable globulin (SHBG) be the protein that bind testosterone, rendering it inaccessible in favour of a woman's physiologic wishes. The enquiry verify that inwardly women subsequent to sexual dysfunction, elevated SHBG in "Oral Contraceptive Discontinued-Users" do not end to values regular with those of "Never-Users of Oral Contraceptive". Thus, in forte of a corollary of the irredeemable elevation in sexual characteristics hormone binding globulin level, tablet user may be at venture for long-standing strength technical hitches, above and beyond as sexual dysfunction.

"EBV be a brilliantly prevalent virus, with capable of 95% of middle-aged adults possessing documentation of viral bring to light according to CDC examination facts," stated Brian Murphy, MD, Chief Medical Officer. "Mononucleosis can utterly destabilize quality-of-life and the acute EBV infectivity may install to other long-term medical sequelae. This double-blind, placebo-controlled, clinical test will dissect fluctuations in viral payload as influenced via valomaciclovir as ably as referee symptom score." "Our laboratory has found valomaciclovir to be a incredibly potent anti-viral agent antagonistic EBV", basis Dr. Henry H. Balfour, Jr., Professor of Pediatrics and Laboratory Medicine and Pathology at the University of Minnesota, who is principal investigator for the study. "If this facts of notion study is dominant, further ample extent study are necessary. We urgently wallow in need of a therapy for this disease that can severely impact the live of babyish adults." The acute mononucleosis study at the University of Minnesota will engrave the resourceful of several premeditated studies of valomaciclovir against EBV connected diseases. Comparative anti-EBV potency data be presented by Professor Balfour's troop at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago in September. A manuscript boast spare data confirm the original helplessness of EBV to valomaciclovir will be submit to a peer-reviewed proven publication shortly.

About Epiphany Biosciences Epiphany Biosciences is set on advance hot therapy for catching disease. Epiphany is now conduct a large Phase 2b study examining the safekeeping and efficacy of valomaciclovir against herpes zoster infection.

Epiphany Biosciences Inc.